|
[1] YOUNOSSI ZM,OTGONSUREN M,HENRY L,et al. Association of nonalcoholic fatty liver disease(NAFLD)with hepatocellular carcinoma(HCC)in the United States from 2004 to2009[J]. Hepatology,2015,62(6):1723-1730.
|
|
[2] CHALASANI N,YOUNOSSI Z,LAVINE JE,et al. The diagnosis and management of nonalcoholic fatty liver disease:Practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology,2018,67(1):328-357.
|
|
[3] YOUNOSSI Z,TACKE F,ARRESE M,et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Hepatology,2019,69(6):2672-2682.
|
|
[4] YOUNOSSI Z,HENRY L. Contribution of alcoholic and nonalcoholic fatty liver disease to the burden of liver-related morbidity and mortality[J]. Gastroenterology,2016,150(8):1778-1785.
|
|
[5] ROMERO-GMEZ M,ZELBER-SAGI S,TRENELL M. Treatment of NAFLD with diet,physical activity and exercise[J]. J Hepatol,2017,67(4):829-846.
|
|
[6] ALKHOURI N,SCOTT A. An update on the pharmacological treatment of nonalcoholic fatty liver disease:Beyond lifestyle modifications[J]. Clin Liver Dis(Hoboken),2018,11(4):82-86.
|
|
[7] LAVINE JE,SCHWIMMER JB,van NATTA ML,et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents:The TONIC randomized controlled trial[J]. JAMA,2011,305(16):1659-1668.
|
|
[8] SANYAL AJ,CHALASANI N,KOWDLEY KV,et al. Pioglitazone,vitamin E,or placebo for nonalcoholic steatohepatitis[J]. N Engl J Med,2010,362(18):1675-1685.
|
|
[9] BRIL F,BIERNACKI DM,KALAVALAPALLI S,et al. Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2diabetes:A randomized controlled trial[J]. Diabetes Care,2019,42(8):1481-1488.
|
|
[10] SHENOY KT,BALAKUMARAN LK,MATHEW P,et al. Metadoxine versus placebo for the treatment of non-alcoholic steatohepatitis:A randomized controlled trial[J]. J Clin Exp Hepatol,2014,4(2):94-100.
|
|
[11] MUSSO G,GAMBINO R,CASSADER M,et al. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease[J]. Hepatology,2010,52(1):79-104.
|
|
[12] SINGH S,SINGH PP,SINGH AG,et al. Anti-diabetic medications and the risk of hepatocellular cancer:A systematic review and meta-analysis[J]. Am J Gastroenterol,2013,108(6):881-891; quiz 892.
|
|
[13] BELFORT R,HARRISON SA,BROWN K,et al. A placebocontrolled trial of pioglitazone in subjects with nonalcoholic steatohepatitis[J]. N Engl J Med,2006,355(22):2297-2307.
|
|
[14] AITHAL GP,THOMAS JA,KAYE PV,et al. Randomized,placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis[J]. Gastroenterology,2008,135(4):1176-1184.
|
|
[15] RATZIU V,GIRAL P,JACQUEMINET S,et al. Rosiglitazone for nonalcoholic steatohepatitis:One-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy(FLIRT)trial[J]. Gastroenterology,2008,135(1):100-110.
|
|
[16] ARMSTRONG MJ,GAUNT P,AITHAL GP,et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis(LEAN):A multicentre,double-blind,randomised,placebo-controlled phase 2 study[J]. Lancet,2016,387(10019):679-690.
|
|
[17] RATZIU V,HARRISON SA,FRANCQUE S,et al. Elafibranor,an agonist of the peroxisome proliferator-activated receptor-αand-δ，induces resolution of nonalcoholic steatohepatitis without fibrosis worsening[J]. Gastroenterology,2016,150(5):1147-1159. e5.
|
|
[18] NEUSCHWANDER-TETRI BA,LOOMBA R,SANYAL AJ,et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic,non-alcoholic steatohepatitis(FLINT):A multicentre,randomised,placebo-controlled trial[J]. Lancet,2015,385(9972):956-965.
|
|
[19] PATEL K,HARRISON SA,ELKASHAB M,et al. Cilofexor,a nonsteroidal FXR agonist,in non-cirrhotic patients with nonalcoholic steatohepatitis:A phase 2 randomized controlled trial[J]. Hepatology,2020.[Online ahead of print]
|
|
[20] HARRISON SA,BASHIR MR,GUY CD,et al. Resmetirom(MGL-3196)for the treatment of non-alcoholic steatohepatitis:A multicentre,randomised,double-blind,placebo-controlled,phase 2 trial[J]. Lancet,2019,394(10213):2012-2024.
|
|
[21] LOOMBA R,LAWITZ E,MANTRY PS,et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis:A randomized,phase 2 trial[J]. Hepatology,2018,67(2):549-559.
|
|
[22] HARRISON SA,WONG VW,OKANOUE T,et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH:Results from randomized phase III STELLAR trials[J]. J Hepatol,2020,73(1):26-39.
|
|
[23] SHIFFMAN M,FREILICH B,VUPPALANCHI R,et al. Randomised clinical trial:Emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease[J]. Aliment Pharmacol Ther,2019,49(1):64-73.
|
|
[24] HARRISON SA,GOODMAN Z,JABBAR A,et al. A randomized,placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis[J]. J Hepatol,2020,72(5):816-827.
|
|
[25] FRIEDMAN SL,RATZIU V,HARRISON SA,et al. A randomized,placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis[J]. Hepatology,2018,67(5):1754-1767.
|
|
[26] HARRISON SA,ABDELMALEK MF,CALDWELL S,et al. Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis[J]. Gastroenterology,2018,155(4):1140-1153.
|
|
[27] HARRISON SA,ROSSI SJ,PAREDES AH,et al. NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis[J]. Hepatology,2020,71(4):1198-1212.
|
|
[28] SANYAL A,CHARLES ED,NEUSCHWANDER-TETRI BA,et al.Pegbelfermin(BMS-986036),a PEGylated fibroblast growth factor 21 analogue,in patients with non-alcoholic steatohepatitis:A randomised,double-blind,placebo-controlled,phase 2a trial[J]. Lancet,2019,392(10165):2705-2717.
|
|
[29] LOOMBA R,KAYALI Z,NOUREDDIN M,et al. GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease[J]. Gastroenterology,2018,155(5):1463-1473. e6.
|
|
[30] ESLAM M,NEWSOME PN,SARIN SK,et al. A new definition for metabolic dysfunction-associated fatty liver disease:An international expert consensus statement[J]. J Hepatol,2020,73(1):202-209.
|
DownLoad: